Recommendations for testing using the N501Y PCR

Overall, prevalence of SARS-CoV-2 in the population remains high and the situation is worrisome due to ongoing transmission. Two newly emerging lineages, the B.1.1.7 (UK variant, N501Y.V1) and the B.1.351 (ZA variant, N501Y.V2), rapidly spread in the United Kingdom, Ireland, and South Africa. Recent modelling data indicates that the N501Y mutations results in a higher transmissibility.

In Switzerland, both variants of concern have been detected shortly before Christmas 2020. Meanwhile, more than 100 isolates of the B1.1.7 lineage were confirmed in different Swiss laboratories. Community transmission within Switzerland has also been documented using whole genome sequencing in selected cases. The B1.351 lineage remains rare. Of note, we only explored a small and strongly biased sample set during December 2020 and first week of January 2021. Further background information on the European and global situation can be found at the ECDC and WHO websites: ECDC: www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-rapidincrease-sars-cov-2-variant-united-kingdom; WHO: www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.

Currently, most commercial based SARS-CoV-2 specific PCR assays cannot identify these variants of concern. Only one exception is noteworthy: the lineage B1.1.7 has a specific deletion at position 21765-770 of the S gene, resulting in a del69-70 of the spike glycoprotein. This deletion results in an S-gene drop out of the Thermo Fisher assay. Due to normal signals of other target genes, this effect was used during the last weeks to identify potential cases of the lineage B1.1.7. Unfortunately, this deletion is not specific for the UK variant. In the Eastern part of Switzerland, where the S-gene drop out continuously increased, this is due to the lineage B1.258, which also shows the deletion and accounts for the majority of cases. Also the S-gene drop out does not include the B1.351 lineage.

For this reason, several diagnostic laboratories and the Federal Office of Public Health developed a screening strategy to rapidly detect the spread of N501Y variants in Switzerland and reduce further community spread with an intensified backward and forward contact tracing through cantonal authorities. The aim is to control for a 2–3 months time period the prevalence of variants of concern using a second PCR. This strategy may slow down an expected increase of case numbers and pressure on the health care system.

Current strategy

The current strategy is to establish an N501Y specific PCR detecting the genetic mutation A23063T in a substantial number of diagnostic laboratories. After this first step to rapidly identify the variant of concern, as a second step, the lineage association should be confirmed using either an amplicon based sequencing approach on the S gene or a whole genome based sequencing approach. Confirmation by sequencing to determine the specific lineage is highly recommended, but requires, according to the FOPH, an initiation by the cantonal physician in charge. Laboratories providing diagnostic sequencing service were mentioned on the SSM website and in a separate document detailed instruction and recommendation regarding the sequencing process were published.

Details on the reporting process as well as re-imbursement are specified within an FOPH letter from Michael Bel. Of note, it is likely that the re-imbursement will only be applicable for a specific time window – as soon as the variants of concern are too prevalent, the N501Y specific PCR will become obsolete.

Available PCR assays to determine the N501Y variant

Different commercial and in house developed PCR systems are able to specifically detect the N501Y variant. Currently, the most common used assay is the SARS Spike N501Y (Light-Mix Kit) from TIB MOLBIOL (reference number 53-0780-96). This assay has been tested with encouraging results by the national reference center (communicated by Prof. Laurent Kaiser, CRIVE). Website of TIB MOLBIOL: https://www.tib-molbiol.de. The CRIVE has also published an in house protocol with details on primers and the PCR steps. The document can be accessed via the following link: www.hug.ch/sites/interhug/files/structures/laboratoire_de_virologie/protocol_amplification_voc_20201201_uk_geneva.pdf

During the first weeks of January 2021, the N501Y specific PCR is already established at the five university centers (Basel, Bern, Geneva, Lausanne, Zurich), Risch AG, Cantonal Hospital Winterthur; and EOC in Bellinzona. Meanwhile, as of 15th February 2021 more than 20 laboratories have established the N501Y specific PCR.

Recommendation key points

The CCCM-SSM strongly recommends that:

(i) Establishment of an N501Y specific PCR by different diagnostic laboratories
(ii) Reporting confirmed N501Y cases and also negative cases (denominator)
(iii) Confirmation using sequencing

The epidemiological information on N501Y positive strains and the introduction of the associated lineages into Switzerland were very recently published in a pre-print journal. Please see: https://www.medrxiv.org/content/10.1101/2021.02.11.21251589v1

1 Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland
2 Applied Microbiology Research, University of Basel, Basel, Switzerland
3 Institute of Microbiology, University Hospital Center of Lausanne, Lausanne, Switzerland